Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Lineage Cell Therapeutics Sold 12M Common Shares To Janus Henderson Investors At A Purchase Price Of $1.75/Share In A Block Transaction Under Its ATM Offering Program; Company Received $21M In Gross Proceeds

Author: Benzinga Newsdesk | November 12, 2025 09:29am

On November 12, 2025, Lineage Cell Therapeutics, Inc. (the "Company") sold 12,000,000 common shares to Janus Henderson Investors at a purchase price of $1.75 per share in a block transaction under its at-the-market offering program. The Company received $21 million in gross proceeds, before deducting fees and other expenses payable by it.

Posted In: LCTX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist